Novo Nordisk (NVO-0.32%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

President Trump threatened to levy a new 50% tariff on E.U.-imported goods last week. Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the ...

President Trump threatened to levy a new 50% tariff on E.U.-imported goods last week. Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the ...

Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up 4.9% as of 10:20 a.m. ET. Where to invest $1,000 right now?

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans.

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually ...

A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ...

As for improving access to obesity treatments, Novo has, in recent months, brought down the out-of-pocket price for Wegovy. In March, it began offering a one-month supply to self-paying customers ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

Novo Nordisk is locked in a patent infringement battle with Dr Reddy’s Laboratories and OneSource Specialty Pharma. SENSEX 82,408.17 + 1,046.30. NIFTY 25,112.40 + 319. ...

Novo Nordisk (NYSE: NVO) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential ...